Skip to main content

Advertisement

SpringerLink
Log in

To What Extent Can Preventive Treatments Prevent Damage From Systemic Lupus Erythematosus?

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Managing lupus patients traditionally involves treating manifestations of active disease with the most effective and least toxic therapies so that “damage” from ongoing disease or treatments can be minimized. Damage in clinical epidemiologic studies is usually defined by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, a validated, organ-specific assessment tool. This review summarizes recent developments regarding organ-specific manifestations and lupus-related damage and their prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Gladman D et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.

    Article  PubMed  CAS  Google Scholar 

  2. Costenbader KH et al. Development and initial validation of a self-assessed lupus organ damage instrument. Arthritis Care Res. 2010;62:559–68.

    Article  Google Scholar 

  3. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.

    Article  PubMed  CAS  Google Scholar 

  4. Lee SS et al. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum. 2008;38:41–54.

    Article  PubMed  CAS  Google Scholar 

  5. Bertoli AM et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage. J Rheumatol. 2008;35:2355–8.

    Article  PubMed  Google Scholar 

  6. Telles R et al. Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus. 2010;19:803–9.

    Article  PubMed  Google Scholar 

  7. Burgos PI et al. Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic cohort (LXIX). Lupus. 2009;18:1303–8.

    Article  PubMed  CAS  Google Scholar 

  8. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56(7):2382–91.

    Article  PubMed  CAS  Google Scholar 

  9. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology. 2009;48(6):673–5.

    Article  PubMed  Google Scholar 

  10. Chambers et al. Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheum. 2009;28:579–85.

    Article  Google Scholar 

  11. Almehed K et al. Prevalence and risk factors of osteoporosis in female SLE patients—an extended report. Rheumatology. 2007;46:1185–90.

    Article  PubMed  CAS  Google Scholar 

  12. Thamer M, Hernan MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009;36(3):560–4.

    Article  PubMed  CAS  Google Scholar 

  13. Fortin PR et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59:1796–804.

    Article  PubMed  CAS  Google Scholar 

  14. Ruiz-Irastorza G et al. Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage. Arthritis Care Res. 2010;62:1160–5.

    Article  CAS  Google Scholar 

  15. Andrade RM et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis. 2008;67:828–34.

    Article  Google Scholar 

  16. Ramsey-Goldman R et al. Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort. Lupus. 2008;17:177–84.

    Article  PubMed  CAS  Google Scholar 

  17. Gonzalez LA et al. Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus. 2009;18:822–30.

    Article  PubMed  CAS  Google Scholar 

  18. • Turchin I et al. Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J Rheumatol 2009; 36:2691-3. This article details another reason to stop smoking: cigarette smoke diminishes the effectiveness of antimalarials in treating cutaneous lupus.

  19. Pons-Estel GJ et al. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res. 2010;62:393–400.

    Article  Google Scholar 

  20. Klein RS et al. The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus. Autoimmun Rev. 2009;8:320–4.

    Article  PubMed  Google Scholar 

  21. Chambers SA et al. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology. 2009;48:673–5.

    Article  PubMed  Google Scholar 

  22. Danila MI et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic cohort. Rheumatology. 2009;48:542–5.

    Article  PubMed  Google Scholar 

  23. Gonzalez LA et al. Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII). Ann Rheum Dis. 2008;67:1170–3.

    Article  PubMed  CAS  Google Scholar 

  24. Urowitz MB, Anton A, Ibanez D, Gladman D. autoantibody response to adjuvant and non-adjuvant H1N1 vaccination. Arthritis Rheum. 2010;62(10):S189.

    Google Scholar 

Download references

Disclosure

Dr. Massarotti has served as a consultant for and had travel/accommodations expenses covered or reimbursed by Genentech, Human Genome Sciences, and and has served as an investigator for EMD Serono and Genentech.

Dr. Schur reported no potential conflicts of interest relevant to this article.

Author information

Authors and Affiliations

  1. Harvard Medical School, Center for Clinical Therapeutics, Division of Rheumatology, Brigham and Women’s Hospital, 75 Francis Street, PBB-B3, Boston, MA, 02115, USA

    Elena M. Massarotti

  2. Harvard Medical School, Brigham and Women’s Hospital Lupus Center, 75 Francis Street, PBB-B3, Boston, MA, 02115, USA

    Peter H. Schur

Authors
  1. Elena M. Massarotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter H. Schur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elena M. Massarotti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Massarotti, E.M., Schur, P.H. To What Extent Can Preventive Treatments Prevent Damage From Systemic Lupus Erythematosus?. Curr Rheumatol Rep 13, 317–323 (2011). https://doi.org/10.1007/s11926-011-0188-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0188-4

Keywords

Search

Navigation